Immunocore (IMCR) vs Innoviva (INVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Innoviva (INVA) has outperformed Immunocore (IMCR) over the past year, gaining 20.1% versus a loss of 14.4%. Over five years, INVA leads with a +25.6% price change compared with -23.4% for IMCR. Innoviva is the larger company by market cap ($1.51 billion vs $1.50 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | INVA |
|---|---|---|
| Share price | $29.09 | $20.87 |
| Market cap | $1.50B | $1.51B |
| 1-day change | -1.09% | -0.90% |
| YTD return | -16.19% | +4.40% |
| 1-year return | -14.42% | +20.15% |
| 5-year return | -23.45% | +25.65% |
| P/E ratio (TTM) | — | 4.88 |
| Forward P/E | — | 9.44 |
| EPS (TTM) | $-0.36 | $4.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.72 | $25.15 |
| 52-week low | $27.56 | $16.52 |
| Distance from 52-week high | -28.55% | -17.02% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +115.64% | +67.70% |
| Average volume | 443.48K | 819.03K |
| Shares outstanding | 51.50M | 72.25M |
| Employees | 524 | 159 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INVA has outperformed IMCR by 34.6 percentage points over the past year.
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About Innoviva
INVA stock →Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees
IMCR vs INVA FAQ
Which is bigger, Immunocore or Innoviva?
Innoviva (INVA) is larger, with a market capitalization of $1.51B compared with $1.50B for Immunocore (IMCR).
Which stock has performed better over the past year, IMCR or INVA?
INVA returned +20.15% over the past 12 months, compared with -14.42% for IMCR (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and Innoviva in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Immunocore and Biotechnology: Pharmaceutical Preparations for Innoviva.